138 related articles for article (PubMed ID: 38310990)
1. Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway.
Li R; Xue C; Pan Y; Li G; Huang Z; Xu J; Zhang J; Chen X; Hou L
J Ethnopharmacol; 2024 May; 326():117778. PubMed ID: 38310990
[TBL] [Abstract][Full Text] [Related]
2. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.
Wang L; Zhou GB; Liu P; Song JH; Liang Y; Yan XJ; Xu F; Wang BS; Mao JH; Shen ZX; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4826-31. PubMed ID: 18344322
[TBL] [Abstract][Full Text] [Related]
3. Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology.
Jiang Z; Sun Y; Wu Z; Tang M; Ye A; Tu B; Yi J; Xu H; Gao Y
J Ethnopharmacol; 2023 Dec; 317():116895. PubMed ID: 37467822
[TBL] [Abstract][Full Text] [Related]
4. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
5. Single-cell transcriptomics profiling the compatibility mechanism of As
Zhang X; Chen H; Huang X; Xu H; Li Y; Yuan H; Yu J; Gao Y
Biomed Pharmacother; 2022 Jul; 151():113182. PubMed ID: 35643069
[TBL] [Abstract][Full Text] [Related]
6. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
[TBL] [Abstract][Full Text] [Related]
7. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
Liao LH; Chen YQ; Huang DP; Wang LN; Ye ZL; Yang LH; Mai HR; Li Y; Liang C; Luo JS; Wang LN; Luo XQ; Tang YL; Zhang XL; Huang LB
Cancer Chemother Pharmacol; 2022 Jul; 90(1):45-52. PubMed ID: 35760920
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
[TBL] [Abstract][Full Text] [Related]
9. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.
Zhang X; Liu L; Yao Y; Gong S; Wang M; Xi J; Chen L; Wei S; Zhang H; Zhao C; Wang H
Trials; 2020 Jan; 21(1):7. PubMed ID: 31898521
[TBL] [Abstract][Full Text] [Related]
10. A novel realgar-indigo naturalis formula more effectively induces apoptosis in NB4 cells.
Xie Q; Yu L; Wang X; Wu Z; Zhi D; Yang J; Guo Z; Wu T; Sun Y; Zhao L; Ding X; Khan A; Li H
Pak J Pharm Sci; 2019 May; 32(3):957-962. PubMed ID: 31278706
[TBL] [Abstract][Full Text] [Related]
11. Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia.
Lou Y; Ma Y; Jin J; Zhu H
Front Oncol; 2020; 10():597601. PubMed ID: 33614484
[TBL] [Abstract][Full Text] [Related]
12. Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
Liu Y; He P; Liu F; Zhou N; Cheng X; Shi L; Zhu H; Zhao J; Wang Y; Zhang M
Tumour Biol; 2014 Apr; 35(4):3421-30. PubMed ID: 24430359
[TBL] [Abstract][Full Text] [Related]
13. Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
Tian Y; Liu Y; He P; Liu F; Zhou N; Cheng X; Shi L; Zhu H; Zhao J; Wang Y; Zhang M
PLoS One; 2014; 9(1):e83184. PubMed ID: 24454695
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.
Huang DP; Yang LC; Chen YQ; Wan WQ; Zhou DH; Mai HR; Li WL; Yang LH; Lan HK; Chen HQ; Guo BY; Zhen ZJ; Liu RY; Chen GH; Feng XQ; Liang C; Wang LN; Li Y; Luo JS; Fan Z; Luo XQ; Li B; Tang YL; Zhang XL; Huang LB
Blood Cancer J; 2023 Dec; 13(1):178. PubMed ID: 38052803
[TBL] [Abstract][Full Text] [Related]
15. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
Luo JS; Zhang XL; Huang DP; Chen YQ; Wan WQ; Mai HR; Chen HQ; Wen H; Liu RY; Chen GH; Li Y; Luo XQ; Tang YL; Huang LB
Ann Hematol; 2023 Jul; 102(7):1713-1721. PubMed ID: 37199788
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
Lou Y; Tong H; Yu W; Wei J; Xu W; Mao L; Jin J
Leuk Res; 2019 Aug; 83():106168. PubMed ID: 31202077
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in Pediatric Acute Promyelocytic Leukemia.
Zhang L; Yang XM; Chen J; Hu L; Yang F; Zhou Y; Zhao BB; Zhao W; Zhu XF
Drug Des Devel Ther; 2021; 15():1633-1640. PubMed ID: 33911851
[TBL] [Abstract][Full Text] [Related]
18. Realgar transforming solution-induced differentiation of NB4 cell by the degradation of PML/RARα partially through the ubiquitin-proteasome pathway.
Hai Y; Wang X; Song P; Li JY; Zhao LH; Xie F; Tan XM; Xie QJ; Yu L; Li Y; Wu ZR; Li HY
Arch Pharm Res; 2019 Aug; 42(8):684-694. PubMed ID: 31214877
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms.
Huang Q; Wang T; Xiong Y; Qu L; Yin Q; Zou W
Chin Herb Med; 2022 Jan; 14(1):154-165. PubMed ID: 36120125
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
